Platelet distribution width as a prognostic factor in patients with COPD – pilot study

Adam J Białas1,2,*
Claudio Pedone1,3,*
Wojciech J Piotrowski1,2
Raffaele Antonelli Incalzi3

1 Department of Pneumology and Allergy, Medical University of Lodz, Łódź, Poland; 2 Healthy Aging Research Centre (HARC), Medical University of Lodz, Łódź, Poland; 3 Department of Geriatrics, Campus Bio-Medico University of Rome, Rome, Italy

*These authors contributed equally to this work

Background: Platelets may actively participate in inflammation in COPD. Platelet distribution width (PDW), a measure of platelets’ volume heterogeneity, may increase in platelets’ activation. We hypothesized that PDW may be a marker of hypercoagulation, which plays a significant role in conditions associated with worse survival of patients with COPD, eg, acute myocardial infarction and other forms of ischemic heart disease.

Methods: Retrospective analysis of 79 patients. Variables were compared after grouping patients according to the upper normal limit of PDW, using Welch’s t-tests or Mann–Whitney U, and chi-square tests. Survival in the two groups was compared using the Kaplan–Meier method and Cox proportional hazards regression.

Results: Ten patients presented values of PDW above 16 fL, which was the upper limit of normality for our laboratory. Compared to patients with normal PDW, they had lower forced expiratory flow between 25% and 75% of vital capacity (FEF 25–75) – 35% of reference value vs 57% (P=0.003) and peak expiratory flow – 39% vs 54% (P<0.001). The median survival of patients with elevated PDW was 743 days compared to those with normal PDW (1,305 days) (P=0.025). The adjusted HR was 4.59 (95% CI: 1.1, 19.19; P=0.04).

Conclusion: Our analysis indicates that elevated PDW is associated with reduced survival of patients with COPD. If our data are to be confirmed, PDW may be used as an inexpensive and repeatable prognostic tool in COPD.

Keywords: COPD, PDW, platelets, inflammation, survival

Background

Increasing evidence suggests that the pathophysiology of COPD is characterized by the interaction between several factors, including local and systemic inflammation. IL-6 plays a central role in the inflammatory process underlying COPD, with increased concentrations reported in plasma, sputum, and exhaled breath of patients with COPD, especially during exacerbations. IL-6 stimulates the synthesis of acute phase proteins, but also affects platelet count by stimulating the differentiation of megakaryocytes into platelets and possibly by stimulating thrombopoietin production.

It has been shown that platelets actively participate in inflammation in several conditions. Upon activation, platelets release chemokines from their α-granules such as MIF, CXCL4, CXCL7 or CXCL5 which play a role in inflammatory processes.

CXCL5 is a chemokine of potential importance in regulation of lung inflammation, by modulating neutrophil transepithelial and transendothelial migration and accumulation in the airspace. Furthermore, platelets regulate MMPs’ activity which significantly contributes to inflammation. Platelets regulate MMPs both directly by secretion of the proteases and their inhibitors, and indirectly by influencing the behavior of other cells such as neutrophils and monocytes. Platelet-derived CD40L, which is shed from the

Correspondence: Adam J Białas
Department of Pneumology and Allergy, Medical University of Lodz, 22 Kopciński avenue 90-153 Lodz, Poland
Tel +48 42 677 6699
Fax +48 42 678 2129
Email adam.bialas@umed.lodz.pl
platelet surfaces by MMPs, induces MT-1-MMP, MMP-1, MMP-2, and MMP-9 on endothelial cells.\textsuperscript{17,18} There is evidence proving the role of these MMPs in the pathophysiology of COPD.\textsuperscript{19–23} The routinely available indices which describe platelets’ morphology and function are the platelet count (PLT), the platelet-to-lymphocyte ratio (PLR), the mean platelet volume (MPV), and the platelet distribution width (PDW). Thrombocytopenia was associated with poor outcomes in acute exacerbations of COPD.\textsuperscript{24} On the other hand, thrombocytosis may be associated with increased short- and long-term mortality after exacerbations.\textsuperscript{25} PLR describes the correlation between changes in levels of platelets and lymphocytes. PLR has been reported to play a significant role in cardiovascular diseases,\textsuperscript{26,27} diabetic ketoacidosis,\textsuperscript{28} and numerous neoplasms.\textsuperscript{8,12,29–40} MPV reflects changes in either the level of platelet stimulation or the rate of platelet production.\textsuperscript{41} It has been assessed as an inflammatory marker in several diseases.\textsuperscript{42–44} COPD patients, during acute exacerbation and in stable phase, have lower MPV compared with healthy controls, and the MPV increases once patients have recovered from exacerbation.\textsuperscript{45} PDW is an index of platelets’ volume heterogeneity\textsuperscript{46} and may increase in platelets’ activation.\textsuperscript{47} The role of PDW has been assessed in several conditions, such as acute gangrenous appendicitis, carotid artery stenosis, coronary artery disease, angina pectoris, idiopathic pulmonary hypertension, ovarian torsion, and preeclampsia.\textsuperscript{48–56} PDW can serve as useful prognostic factor for long-term mortality in patients with acute myocardial infarction and was found to be an independent risk factors for cardiovascular mortality.\textsuperscript{57} Because hypercoagulation may play a significant role in conditions associated with worse survival of patients with COPD,\textsuperscript{58,59} we hypothesized that PDW may be associated with survival in these patients. The objective of this study was to evaluate the mortality rate of patients with COPD with and without an abnormal PDW.

Methods
From the electronic archive of the Campus Bio-Medico Hospital in Rome, Italy, between March 2006 and December 2014, we identified 288 patients with post-bronchodilator forced expiratory volume in 1 second to forced vital capacity ratio (FEV\textsubscript{1}/FVC) <0.7 and for whom information on vital status could be obtained from the regional death registry. Subsequently, we selected patients with a blood cell count performed within 2 weeks of the index spirometry (N: 92). We excluded patients with conditions that, based on the available evidence, may affect PDW: acute exacerbation of COPD, any active acute inflammation, connective tissue disorder, diabetic ketoacidosis, recent history of myocardial infarction, end-stage renal disease, history of any active malignancy, and hematological system diseases, or blood transfusion in the last 2 months.

Demographic data, medical history, and routine laboratory measurements, including white blood count, neutrophils, lymphocytes, PLT, MPV, and PDW, were collected from the digital database of medical records of Campus Bio-Medico di Roma.

Pulmonary function tests (PFTs) including vital capacity (VC), FVC, FEV\textsubscript{1}, FEV\textsubscript{1}/FVC ratio, peak expiratory flow between 25% and 75% of VC (FEF 25–75), peak expiratory flow (PEF), total lung capacity (TLC), and residual volume, were collected from the digital database of medical records of Campus Bio-Medico di Roma.

Survival analysis was performed after grouping patients according to the laboratory upper limit of PDW, using \textit{t}-test for normally distributed continuous data, and Mann–Whitney \textit{U} test for not normally distributed continuous data. Categorical variables were compared using chi-square test with Yates’ continuity correction.

Data were analyzed using R software for MacOS (R Core Team [2016]. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria).

The protocol of the study was approved by the Ethics Committee of the Campus Bio-Medico University.

Results
Seventy-nine patients met the inclusion criteria. The flow chart of sample selection is reported in Figure 1. Most patients
were GOLD stage II (49.4%), ex-smokers (62.5%), and had comorbidities (90%). Mean age of the study population was 73.6 (95% CI: 72.32, 74.95). The overall male-to-female ratio was 1.93:1. The means of baseline values of the study population are presented in Table 1.

Ten patients presented values of PDW above 16 fL, which was the upper limit of normality for our laboratory. There were no differences in age and gender distribution between the groups. Participants with higher PDW showed significantly lower FEF 25–75 and PEF values compared to those with normal PDW – both in absolute values, and expressed as percent of reference value (Table 2).

Patients with high PDW had worse survival compared to patients with normal PDW, with a median survival time of 743 days compared to 1,305 days of patients with normal PDW (Figure 2). Log rank test showed significant differences between groups (chi-square =4.9; P=0.025). Abnormal PDW values were associated with an RR of death of 3.18 (95% CI: 0.6, 7.79; P=0.04). Abnormal PDW ratio was 1.93:1. The means of baseline values of the study population are presented in Table 1.

Table 1 Baseline values of the study population

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC (×10^3/µL)</td>
<td>7.06</td>
<td>6.63, 7.49</td>
</tr>
<tr>
<td>Neutrophils (×10^3/µL)</td>
<td>4.26</td>
<td>3.89, 4.63</td>
</tr>
<tr>
<td>Lymphocytes (×10^3/µL)</td>
<td>2.08</td>
<td>1.87, 2.3</td>
</tr>
<tr>
<td>Platelet count (×10^3/µL)</td>
<td>224.1</td>
<td>202.58, 245.55</td>
</tr>
<tr>
<td>MPV (fL)</td>
<td>10.91</td>
<td>10.69, 11.13</td>
</tr>
<tr>
<td>PDW (fL)</td>
<td>13.36</td>
<td>12.9, 13.8</td>
</tr>
<tr>
<td>PLR</td>
<td>123.13</td>
<td>108.82, 137.44</td>
</tr>
</tbody>
</table>

Pre-bronchodilator

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>VC (L)</td>
<td>2.49</td>
<td>2.3, 2.67</td>
</tr>
<tr>
<td>FVC (L)</td>
<td>2.47</td>
<td>2.28, 2.65</td>
</tr>
<tr>
<td>FVC (%)</td>
<td>76.09</td>
<td>72, 80.17</td>
</tr>
<tr>
<td>FEV1 (L)</td>
<td>1.47</td>
<td>1.33, 1.6</td>
</tr>
<tr>
<td>FEV1 (%)</td>
<td>59.29</td>
<td>54.92, 63.67</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>0.59</td>
<td>0.57, 0.61</td>
</tr>
<tr>
<td>FEF 25–75 (L/s)</td>
<td>0.7</td>
<td>0.62, 0.78</td>
</tr>
<tr>
<td>FEF 25–75 (%)</td>
<td>36.1</td>
<td>32.35, 39.86</td>
</tr>
<tr>
<td>PEF (%)</td>
<td>3.68</td>
<td>3.32, 4.04</td>
</tr>
<tr>
<td>PEF (%)</td>
<td>45.57</td>
<td>41.62, 49.52</td>
</tr>
</tbody>
</table>

Post-bronchodilator

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>VC (L)</td>
<td>2.7</td>
<td>2.52, 2.89</td>
</tr>
<tr>
<td>FVC (L)</td>
<td>2.68</td>
<td>2.5, 2.87</td>
</tr>
<tr>
<td>FVC (%)</td>
<td>82.78</td>
<td>78.84, 86.73</td>
</tr>
<tr>
<td>FEV1 (L)</td>
<td>1.62</td>
<td>1.48, 1.75</td>
</tr>
<tr>
<td>FEV1 (%)</td>
<td>65.29</td>
<td>60.9, 69.67</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>0.6</td>
<td>0.57, 0.62</td>
</tr>
<tr>
<td>FEF 25–75 (L/s)</td>
<td>0.996</td>
<td>0.89, 1.1</td>
</tr>
<tr>
<td>FEF 25–75 (%)</td>
<td>54.5</td>
<td>47.37, 61.62</td>
</tr>
<tr>
<td>PEF (%)</td>
<td>4.01</td>
<td>3.66, 4.36</td>
</tr>
<tr>
<td>PEF (%)</td>
<td>51.91</td>
<td>46.66, 57.16</td>
</tr>
<tr>
<td>TLC (L)</td>
<td>4.89</td>
<td>4.63, 5.15</td>
</tr>
<tr>
<td>RV (L)</td>
<td>2.42</td>
<td>2.27, 2.57</td>
</tr>
</tbody>
</table>

Table 2 Distribution of patients

<table>
<thead>
<tr>
<th>Comorbidities</th>
<th>Number of patients</th>
<th>Percent (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory</td>
<td>14</td>
<td>17.7</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>63</td>
<td>79.7</td>
</tr>
<tr>
<td>Mental</td>
<td>9</td>
<td>11.4</td>
</tr>
<tr>
<td>Endocrine system</td>
<td>11</td>
<td>13.9</td>
</tr>
<tr>
<td>Central nervous system</td>
<td>10</td>
<td>12.7</td>
</tr>
<tr>
<td>Diabetes mellitus type 2</td>
<td>18</td>
<td>22.8</td>
</tr>
<tr>
<td>Other</td>
<td>47</td>
<td>59.5</td>
</tr>
</tbody>
</table>

Smoking history

<table>
<thead>
<tr>
<th>Smoking history</th>
<th>Number of patients</th>
<th>Percent (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoker</td>
<td>18/72</td>
<td>25</td>
</tr>
<tr>
<td>Non-smoker</td>
<td>9/72</td>
<td>12.5</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>45/72</td>
<td>62.5</td>
</tr>
</tbody>
</table>

GOLD

<table>
<thead>
<tr>
<th>Stage</th>
<th>Number of patients</th>
<th>Percent (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>20</td>
<td>25.3</td>
</tr>
<tr>
<td>II</td>
<td>39</td>
<td>49.4</td>
</tr>
<tr>
<td>III</td>
<td>17</td>
<td>21.5</td>
</tr>
<tr>
<td>IV</td>
<td>3</td>
<td>3.8</td>
</tr>
</tbody>
</table>

Notes: Smoker history was reported in 72 records.

Abbreviations: FEF 25–75, forced expiratory flow between 25% and 75% of vital capacity; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; MPV, mean platelet volume; PDW, platelet distribution width; PEF, peak expiratory flow; PLR, platelet-to-lymphocyte ratio; RV, residual volume; TLC, total lung capacity; VC, vital capacity; WBC, white blood count.

Discussion

In our study, we found that elevated PDW was associated with increased risk for mortality in COPD patients. This result was confirmed after adjustment for age, comorbidities, and FEV1%, suggesting that in our sample PDW was an independent risk factor for mortality.

Activation of platelets causes morphological changes, including pseudopodia formation. Pseudopodium formation...
Table 2 Functional and demographic parameters of the study population according to upper limit of PDW values

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PDW ≤16 (fL)</th>
<th>PDW &gt;16 (fL)</th>
<th>Mean difference</th>
<th>Comparison result</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=69</td>
<td>n=10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>Mean</td>
<td>95% CI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>73.57</td>
<td>74.1</td>
<td>0.64</td>
<td>0.64</td>
<td></td>
</tr>
<tr>
<td>WBC (×10³/µl)</td>
<td>7.05</td>
<td>7.15</td>
<td>0.89</td>
<td>0.89</td>
<td></td>
</tr>
<tr>
<td>Neutrophils (×10³/µl)</td>
<td>4.28</td>
<td>4.14</td>
<td>0.15</td>
<td>-0.97, 1.26</td>
<td>0.8</td>
</tr>
<tr>
<td>Lymphocytes (×10³/µl)</td>
<td>2.05</td>
<td>2.26</td>
<td>0.63</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platelet count (×10³/µl)</td>
<td>229.94</td>
<td>183.5</td>
<td>46.44</td>
<td>-17.74, 110.63</td>
<td>0.15</td>
</tr>
<tr>
<td>MPV (fL)</td>
<td>10.68</td>
<td>12.52</td>
<td>-1.84</td>
<td>-2.36, -1.32</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PLR</td>
<td>125.34</td>
<td>107.89</td>
<td>4.44</td>
<td></td>
<td>0.42</td>
</tr>
<tr>
<td>VC (L)</td>
<td>2.67</td>
<td>2.9</td>
<td>-0.23</td>
<td>-0.79, 0.32</td>
<td>0.4</td>
</tr>
<tr>
<td>FVC (L)</td>
<td>2.65</td>
<td>2.89</td>
<td>-0.24</td>
<td>-0.8, 0.32</td>
<td>0.4</td>
</tr>
<tr>
<td>FVC (%)</td>
<td>82.64</td>
<td>83.8</td>
<td>-1.17</td>
<td>-13.1, 10.76</td>
<td>0.85</td>
</tr>
<tr>
<td>FEV, (L)</td>
<td>1.59</td>
<td>1.82</td>
<td>-0.23</td>
<td>-0.65, 0.18</td>
<td>0.26</td>
</tr>
<tr>
<td>FEV, (%)</td>
<td>64.69</td>
<td>69.37</td>
<td>-4.68</td>
<td>-17.9, 8.54</td>
<td>0.48</td>
</tr>
<tr>
<td>FEV/FVC</td>
<td>0.6</td>
<td>0.57</td>
<td>0.07</td>
<td></td>
<td>0.2</td>
</tr>
<tr>
<td>FEF 25–75 (L/s)</td>
<td>1.04</td>
<td>0.69</td>
<td>0.35</td>
<td>0.11, 0.59</td>
<td>0.007</td>
</tr>
<tr>
<td>FEF 25–75 (%)</td>
<td>57.27</td>
<td>35.4</td>
<td>21.87</td>
<td>8.16, 35.58</td>
<td>0.003</td>
</tr>
<tr>
<td>PEF (L/s)</td>
<td>4.13</td>
<td>3.17</td>
<td>0.96</td>
<td>0.32, 1.61</td>
<td>0.005</td>
</tr>
<tr>
<td>PEF (%)</td>
<td>53.85</td>
<td>38.54</td>
<td>15.31</td>
<td>6.82, 23.78</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TLC (L)</td>
<td>4.9</td>
<td>4.79</td>
<td>0.11</td>
<td>-0.64, 0.88</td>
<td>0.76</td>
</tr>
<tr>
<td>RV (L)</td>
<td>2.39</td>
<td>2.65</td>
<td>0.25</td>
<td></td>
<td>0.25</td>
</tr>
</tbody>
</table>

Number of patients and percent

| Gender                                  | n=69         | n=10         |                  |                   |        |
|                                        | Male         | Female       |                  |                   |        |
|                                        | 44 (63.77%)  | 25 (36.23%)  |                  |                   |        |
| Smoking history                         | 63           | 9            |                  |                   | 0.91   |
|                                        | Smoker       | Non-smoker   | Ex-smoker        |                   |        |
|                                        | 15 (23.81%)  | 8 (12.7%)    | 40 (63.49%)      |                  |        |
| GOLD stages of airway obstruction       |              |              |                  |                   | 0.90   |
| I                                       | 16 (23.19%)  | 4 (40%)      |                  |                   | 0.81   |
| II                                      | 35 (50.72%)  | 4 (40%)      |                  |                   | 0.98   |
| III                                     | 15 (21.74%)  | 2 (20%)      |                  |                   | 0.88   |
| IV                                      | 3 (4.35%)    | 0            |                  |                   | 0.44   |
| Comorbidities                           |              |              |                  |                   |        |
| Respiratory                             | 13 (18.84%)  | 1 (10%)      |                  |                   | 0.82   |
| Cardiovascular                          | 55 (79.71%)  | 8 (80%)      |                  |                   | 0.88   |
| Mental                                  | 8 (11.59%)   | 1 (10%)      |                  |                   | 0.92   |
| Endocrine system                        | 9 (13.04%)   | 2 (20%)      |                  |                   | 0.44   |
| Central nervous system                  | 10 (14.49%)  | 0            |                  |                   | 0.82   |
| Diabetes mellitus type 2                | 16 (23.19%)  | 2 (20%)      |                  |                   | 0.82   |
| Other                                   | 40 (57.97%)  | 7 (70%)      |                  |                   | 0.7    |

Number of patients and percent

Notes: *P*-value for Mann–Whitney U test. ⁴Post-bronchodilator values.

Abbreviations: FEF 25–75, forced expiratory flow between 25% and 75% of vital capacity; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; MPV, mean platelet volume; PDW, platelet distribution width; PEF, peak expiratory flow; PLR, platelet-to-lymphocyte ratio; RV, residual volume; TLC, total lung capacity; VC, vital capacity; WBC, white blood count.

Enhances platelet–surface interactions (adhesion) and platelet–platelet interaction (cohesion).⁶⁴ Progressively activated platelets with pseudopodia formation have heterogeneous size, and PDW may increase.⁴⁷ The association of PDW with survival may be hypothetically linked with hypercoagulation, which plays a significant role in conditions associated with survival in COPD, eg, acute myocardial infarction and other forms of ischemic heart disease.⁵⁸,⁵⁹
According to Wang et al, elevated PDW is a risk factor for pulmonary embolism and may be observed in COPD patients with this condition.65

Our results are in line with other evidence which shows that PDW may be a marker of COPD exacerbations,66 while patients with stable COPD do not seem to have higher PDW compared to controls.67 Furthermore, the use of antiplatelet drugs was associated with improved survival in oxygen-dependent COPD patients.68

While we excluded patients with diseases with an obvious impact on PDW or inflammation, in our sample, comorbidities were common, eg, prevalence of diabetes mellitus was 23%. Makhlof et al showed that COPD patients with diabetes mellitus had significantly higher PDW compared to healthy controls, but there was no difference in PDW between COPD patients with and without diabetes mellitus.69

We found significantly lower values of FEF 25–75 and PEF among patients with elevated PDW. This is a novel finding in a population of patients with COPD. Indeed, FEF 25–75 reflects the expiratory flows in peripheral airways, whereas PEF is strictly dependent upon the strength of expiratory muscles. Thus, these findings, though preliminary in nature, suggest that higher PDW, as a marker of inflammatory and hypercoagulable status, is linked to lung metabolism/inflammation and sarcopenia. Unfortunately, we lacked additional information, such as breath pattern analysis and direct measurement of respiratory muscle strength, to test this hypothesis. However, we think that it is unlikely that PDW per se has any direct effect on pulmonary function. The associations that we have found are most likely due to platelet morphology acting as a marker for some other biological process, such as inflammation. Due to the retrospective character of our study, causal relationship cannot be verified, and our results must also be interpreted in light of the fact that both of these parameters have limited clinical value in COPD, while we found no difference in spirometric parameters known to have important prognostic significance (FEV1, FVC). Measurement of FEF 25–75 does not contribute to clinical decision making.70 PEF is recorded in the first tenth of a second of forced expiration, while FEV1 continues to record forced expiration for a further 0.9 s, therefore FEV1 records what happens to expired air after peak flow is reached. It is in this component of forced expiration that the changes characteristic of COPD are observed.71

There are some limitations of our study that need to be taken into account. Our sample size is relatively small and we could not fully investigate the relationship between PFT and PDW. Furthermore, our study is a retrospective analysis and we have to be aware of a risk of selection bias.

Conclusion
Our pilot analysis shows that PDW is associated with survival in patients with COPD. As it can be simply and rapidly measured from routine blood examination, should our results be confirmed in larger samples, it may prove to be a widely available, inexpensive, and repeatable prognostic marker. Furthermore, it might contribute to the characterization of the phenotypic variability of COPD.

Author contributions
AJB – study conception, design, and coordination, acquisition of data, analysis, and interpretation of data, statistical analysis, drafting of manuscript; CP – study conception, design, and coordination, acquisition of data, analysis and interpretation of data, statistical analysis, drafting of manuscript; WJP – contributed to the design of the study, analysis, and interpretation of data, critical revision; RAI – study design and coordination, analysis and interpretation of data, critical revision, drafting of manuscript. All authors edited and approved the final version of the manuscript.

Disclosure
The authors report no conflicts of interest in this work.

References


70. Quanjer P, Weiner DJ, Pretto JJ, Brazzale DJ, Boros PW. Measurement of FEV25%–75% and FEV75% does not contribute to clinical decision making. Eur Respir J. 2014;43(4):1051–1058.